Impact Therapeutics, a Chinese cancer-drug developer, aims to raise up to $117 million in a Hong Kong initial public offering, according to a term sheet seen by Reuters on Tuesday.
Impact is offering 41.98 million shares at $19.75-21.75 ($2.52 to $2.78) each.
The deal could rise to $134 million if underwriters use an over-allotment option.
Six cornerstone investors, including Tencent, will buy about $35.7 million of the stock.
Impact expects to price the IPO on May 11 and list on May 13.
Reuters
